OrbisResearch.com has published new research report on “ Hepatitis B Industry Pipeline Review, H2 Analysis ” to its database
Hepatitis B – Pipeline Review, H2 2016, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/152652 .
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hepatitis B – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 10, 24, 18, 3, 58, 33 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 7 and 6 molecules, respectively.Hepatitis B.
Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse the full report @ http://www.orbisresearch.com/reports/index/hepatitis-b-pipeline-review-h2-2016 .
– The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/152652 .
AiCuris GmbH & Co KG
AIMM Therapeutics BV
Akshaya Bio Inc
Alnylam Pharmaceuticals Inc
AlphaMab Co., Ltd
Amarna Therapeutics BV
Arbutus Biopharma Corp
Arcturus Therapeutics Inc
Arrowhead Pharmaceuticals Inc
Assembly Biosciences Inc
Beijing Kawin Technology Share-Holding Co Ltd
Beijing Minhai Biotechnology Co Ltd
Benitec Biopharma Ltd
Biological E Ltd
BioStar Pharmaceuticals Inc
Bolder Biotechnology Inc
BrightGene Bio-Medical Technology Co Ltd
Bukwang PharmCo Ltd
Chong Kun Dang Pharmaceutical Corp
Chromis Therapeutics, Inc.
ChronTech Pharma AB
Cocrystal Pharma Inc
ContraVir Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Dong-A Socio Holdings Co Ltd
Dynavax Technologies Corp
Ensemble Therapeutics Corp
eTheRNA Immunotherapies NV
F. Hoffmann-La Roche Ltd
GeoVax Labs Inc
Gilead Sciences Inc
Green Cross Corp
Hanmi Pharmaceuticals Co Ltd
HEC Pharm Co., Ltd.
Humabs BioMed SA
Huons Co Ltd
Ildong Pharmaceutical Co Ltd
Indian Immunologicals Ltd
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
ISA Pharmaceuticals BV
Jiangsu Hansoh Pharmaceutical Co Ltd
Johnson & Johnson
LG Life Science LTD
Ligand Pharmaceuticals Inc
MultiCell Technologies Inc
Oncolys BioPharma Inc
Panacea Biotec Ltd
Profectus BioSciences Inc
Redx Pharma Plc
Rodos BioTarget GmbH
Samjin Pharmaceutical Co Ltd
Sanofi Pasteur SA
Shantha Biotechnics Ltd
Sinovac Biotech Ltd
Spring Bank Pharmaceuticals Inc
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
TCM Biotech International Corp
Vaxine Pty Ltd
VBI Vaccines Inc
VLP Biotech Inc
Zydus Cadila Healthcare Ltd
For any enquires before buying, connect with us @ firstname.lastname@example.org
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact email@example.com